Drug Trial Radar · NCT05794139
Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy
Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
52
Actual
Start
Sep 21, 2023
Primary completion
May 11, 2026
Study completion May 18, 2026
Sponsor
- Lead sponsor
- NMD Pharma A/SIndustry
- Sponsor type
- Industry
- First posted
- Apr 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of NMD670 in the treatment of ambulatory adults with spinal muscular atrophy type 3
Conditions
- Spinal Muscular Atrophy
Interventions
NMD670Drug
Tablets
PlaceboDrug
Tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in 6 minute walk test (6MWT) total distance versus placeboTime frame: Baseline to day 21
Locations
25 sites in 8 countries. Site status is shown where the registry gives one.
UCLA David Geffen School Of Medicine - Neurology
Los Angeles, California
Stanford University Medical Center
Palo Alto, California
University of Kansas Medical Center
Kansas City, Kansas
The Johns Hopkins Medicine, Spinal Muscular Atrophy Center
Baltimore, Maryland
Roy Blunt NextGen Precision Health Institute
Columbia, Missouri
Washington University School of Medicine
St Louis, Missouri
Rare Disease Research - Raleigh-Durham
Hillsborough, North Carolina
The Ohio State University Wexner Medical Center
Columbus, Ohio
Neurology Rare Disease Center
Denton, Texas
UZ Leuven - Neurochirurgie Campus Gasthuisberg
Leuven, Belgium
CHR de la Citadelle - Neurologie
Liège, Belgium
Heritage Medical Research Clinic
Calgary, Canada
Genge Partners Inc.
Montreal, Canada
Aarhus Universitetshospital, Neurologisk Afdeling
Aarhus, Denmark
Rigshospitalet - Neurologisk Afdeling
Copenhagen, Denmark
Charite - Campus Virchow-Klinikum (CVK)
Berlin, Germany
Universitätsklinikum Essen - Klinik Für Neurologie
Essen, Germany
Istituto Giannina Gaslini, IRCCS
Genova, Italy
Istituto Neurologico C. Besta, Fondazione IRCCS
Milan, Italy
Ospedale Niguarda, ASST Grande Ospedale Metropolitano Niguarda
Milan, Italy
AOU Città della Salute e della Scienza di Torino
Torino, Italy
Universitair Medisch Centrum Utrecht, locatie Academisch Zie - Neurology
Utrecht, Netherlands
Hospital Universitari Vall D Hebron
Barcelona, Spain
Hospital Materno Infantil La Paz
Madrid, Spain
Hospital Universitario y Politécnico La Fe
Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.